It was already one of the projects of his predecessor. Olivier Brandicourt was disappointed in it does not tackle in depth the organization of Sanofi, is still too heavy and bureaucratic. This leads to its competitiveness, which has eroded in the face of other Big Pharma. Its operating margin rose 16.13 % to 13,11 % between 2015 and 2018. "Novartis and GSK have made risky gambles to raise, observes Jean-Jacques Le Fur, an analyst at Bryan Garnier. Sanofi has yet to streamline its organization. There can be no recovery of research and development if the laboratory does not regain efficiency on the whole chain."

This is to create more fluidity to optimize both the decision-making process and the execution of the strategy. Olivier Brandicourt has been appointed eighteen months Dominique Carouge, twenty-eight years of house, the head of the transformation of Sanofi. The appointment of ...